GuidelineHNO2026
[German S2k guideline on antibiotic therapy of ENT infections : The most important information in brief].
Guideline in HNO, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotics save lives, but their long-term side effects are often underestimated. To prevent side effects and maintain the effectiveness of antibiotics, uncomplicated infections should be treated as narrowly as possible, while life-threatening infections should be treated as broadly as necessary. Acute upper respiratory tract infections should only be treated with antibiotics if there is a clear bacterial cause and the infection is severe. Penicillin V is the first-line treatment for tonsillopharyngitis, amoxicillin for acute otitis media (AOM) and acute rhinosinusitis (ARS), and a group 1 cephalosporin for furuncles and skin phlegmons. For severe infections with possible involvement of anaerobic bacteria (abscesses of the mouth and throat, oto- and sinogenic complications), aminopenicillin-beta-lactamase combination therapy is the first choice. Fluoroquinolones, cephalosporins (except group 1), clindamycin, and carbapenems should only be used in well-founded exceptional cases.
Indexed as
Identifiers
42230387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.